Interestingly, through sequencing analysis of normal karyotype AML patients with CEBPA mutations in recent years, researchers have found that Tet methylcytosine dioxygenase 2 (TET2) and GATA2 mutations are more likely to occur in biCEBPA patients (approximately 30%), while CEBPA single mutation (moCEBPA) patients are more likely to have combined NPM1, FLT-ITD/TKD and IDH2 mutations, and the prognosis is relatively poor when combined with TET2 mutations (15, 16). This evidence concerns the gene TET2 and acute myeloid leukemia.